Momepax Control (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This binding modifies gene expression, suppressing the production of inflammatory mediators such as cytokines and chemokines, which reduces swelling, mucus production and the overall allergic response.

The appropriate dose of Momepax Control is determined by a qualified prescriber based on the patient’s age, severity of symptoms and clinical guidelines. Patients should follow the specific instructions provided on the prescription label and by their healthcare professional.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before starting treatment.

To request Momepax Control, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Momepax Control (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with older agents such as beclomethasone, it often provides stronger anti‑inflammatory effects at lower doses, leading to effective symptom control with minimal systemic absorption.

Store Momepax Control at room temperature, below 25 °C (77 °F). Keep the spray bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Momepax Control is administered as a nasal spray. The patient gently shakes the bottle, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious, though rare, risks include nasal septal perforation, severe nosebleeds, adrenal suppression leading to systemic corticosteroid effects, and opportunistic fungal infections of the nasal cavity. Patients should seek medical attention if they notice persistent bleeding, unusual fatigue, or visual changes.

Momepax Control should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated fungal, viral or bacterial infections of the nasal passages until the infection has been resolved.